PTEN-mutant ER + metastatic breast cancer [168]Estrogen receptor + HER2- metastatic/advanced breast cancer with aromatase inhibitor resistance [169]Metastatic triple-negative breast cancer [170]. This evidence concerns the gene CYP19A1 and triple-negative breast carcinoma.